Company intelligence / Profile preview

CY Holdings

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

CY Pharmaceutical is a clinical-stage biotechnology company focused on developing innovative therapies for metabolic and liver diseases. The company's primary research efforts are directed toward addressing unmet medical needs in Type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). Their lead programs utilize small molecule and peptide-based approaches to target metabolic pathways, including the GLP-1 receptor. CY Pharmaceutical aims to provide more effective and accessible treatment options for patients suffering from chronic metabolic conditions through its specialized drug development pipeline.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on CY Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CY Holdings.

Explore the full profile